SURFACE GUIDED ADJUVANT RADIOTHERAPY TATTOO-FREE FOR BREAST CANCER
PO-1845
Abstract
SURFACE GUIDED ADJUVANT RADIOTHERAPY TATTOO-FREE FOR BREAST CANCER
Authors: Rosilda Cuscito1, Federica Fragnoli1, Chiara Indelicati1, Giuseppe Sanfrancesco2, Christian De Pascali1, Marina De Masi1, Rosalinda Parabita1, Alberto Aga1, Francesco Berloco1, Luciana Brana'1, Annarita Ciocia1, Domenico Curci1, Gianluca Ladisa1, Mariella Nardiello1, Daniela Nardelli1, Valeria De Candia1, Fabiana Gregucci1, Alessia Surgo1, Roberta Carbonara1, Maria Paola Cliliberti1, Morena Caliandro1, Ilaria Bonaparte1, Alba Fiorentino1
1Miulli General Regional Hospital, Radiation Oncology, Acquaviva delle Fonti - Bari, Italy; 2Miulli General Regional Hospital, Radiation Oncology, Miulli General Regional Hospital, Italy
Show Affiliations
Hide Affiliations
Material and Methods
Patients
with BC received lumpectomy + adjuvant hypofractionated whole breast RT with
simultaneous integrated boost on tumor bed for a total dose respectively of
40.5Gy and 48Gy in 15 fractions. During simulation procedures, all patients
were immobilized in a supine position and underwent to a planning CT (2 mm
slide thickness) without skin tattoo using a system of SGRT (Optical Surface
Monitor System AlignRT®) to register and verify patients’ position. An expansion of 6mm in the transverse direction and 8mm in cranial–caudal
direction was applied from CTV to PTV. The treatment was delivered using an FFF-VMAT technique. For each treatment session, match
values of all 3 translational and 3
rotational axes were recorded. To evaluate inter-fraction variability, daily portal images were performed, revising setup
treatment position, and acquiring data. To evaluate intra-fraction variations,
SGRT was applied, acquiring data regarding final patient’s position at the end
of RT.
Data regarding acute side effects were collected weekly during RT and
at the end of treatment according to RTOG radiation morbidity scoring system.
Results
Between 01/2021-04/2021, a total of 375 treatment sessions were
analyzed in 25 women. Clinical data were summarized in Table 1. Inter-fraction mean
values (±SD) (IC95%) were as follow: longitudinally 2.2mm (±1.6) (2-2.4),
laterally 1.4mm (±1.1) (1.2-1.5), vertically 1.8mm (±1.5) (1.6-1,9), roll 0.0°
(±0.3) (0.03-0.1), pitch 0.8° (±0.6°) (0.8-0.9), yaw 0.67° (±0.53°) (0.6-0.7). Intra-fraction
mean values (±SD) (IC95%) were: longitudinally 0.12mm (±0.11mm) (0.1-0.13),
laterally 0.07mm (±0.07mm) (0.06-0.08), vertically 0.12mm (±0.12mm) (0.1-0.13),
roll 0.33° (±0.34°) (0.28-0.37), pitch 0.43° (±0.49°) (0.36-0.49), yaw 0.35°
(±0.44°) (0.29-0.4). Median and IQR values were showed in Figure 1.
All patients completed their treatment. G0 acute skin toxicity was
recorded in 13 (52%) cases and G1 in 12 (48%) cases. No skin toxicity≥2 was observed or other types of side
effects.
Conclusion
The analysis shows that the SGRT-guided tattoo-free approach in
breast RT is a reproducible and safe treatment suggesting that radiological
imaging could be reduced to verify treatment patients’ position.